抗VEGF难治性视网膜下液与更好视力及更低黄斑萎缩风险相关
结果显示,第3个月残留SRF与第12和24个月更低的MA发生率相关,且残留SRF任何厚度均与更高的平均BCVA相关,但BCVA变化无差异。难治性SRF在2年内对视力结局无不利影响。
要点
- 第3个月残留SRF与第12和24个月更低的MA发生率相关。
- 残留SRF任何厚度均与更高的平均BCVA相关,但BCVA变化无差异。
- 难治性SRF在2年内对视力结局无不利影响。
核心结论
- 难治性视网膜下液在2年内对视力结局无不利影响,且与更低的黄斑萎缩发生率相关。
主要发现
- 在基线无MA的眼中,第3个月残留SRF对比无SRF与第12个月MA率(5.1% vs 22.1%)和第24个月MA率(13.3% vs 31.2%)更低相关(均p<0.0001)。
- 第6个月残留SRF患者的第12和24个月MA百分比相似。
- 基线SRFV更高与更低的MA率相关。
- 残留SRF任何厚度(>0-50 µm:71.2字母;>50-100 µm:71.3字母;>100 µm:69.2字母)对比无SRF(63.6字母)的平均BCVA更高。
- 第3或6个月有或无难治性SRF的眼从基线到第12或24个月的BCVA变化相同。
关键数值与推荐
- SRF厚度分组:0、>0-50、>50-100和>100 µm;SRF存在、厚度和SRFV由SD-OCT确定。
- MA通过荧光素血管造影、彩色眼底照相和SD-OCT识别。
临床怎么用
- 对于接受雷珠单抗治疗的新生血管性AMD眼,难治性SRF的存在不应被视为视力预后不良的标志。
- 残留SRF可能与更低的黄斑萎缩风险相关,临床决策时可综合考虑。
局限性
- 为HARBOR试验的事后分析,所有治疗组汇总,结果需谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND/AIM: To evaluate relationships between subretinal fluid (SRF), macular atrophy (MA) and visual outcomes in ranibizumab-treated neovascular age-related macular degeneration (nAMD). METHODS: This post hoc HARBOR trial (NCT00891735) analysis included ranibizumab-treated (0.5 or 2.0 mg, monthly or as-needed, all treatment arms pooled) eyes with nAMD and baseline (screening, baseline and week 1) SRF. SRF presence, SRF thickness (0, >0-50, >50-100 and >100 µm) and subretinal fluid volume (SRFV) were determined by spectral domain optical coherence tomography (SD-OCT). Best-corrected visual acuity (BCVA) was assessed. MA was identified using fluorescein angiograms and colour fundus photographs, as well as SD-OCT. RESULTS: Seven hundred eighty-five of 1097 eyes met analysis criteria. In eyes without baseline MA, residual versus no SRF at month (M) 3 was associated with lower MA rates at M12 (5.1% vs 22.1%) and M24 (13.3% vs 31.2%) (both p<0.0001); MA percentages at M12/M24 were similar among patients with residual SRF at M6. Higher baseline SRFV was associated with a lower MA rate. Greater mean BCVA was observed with residual SRF of any thickness (>0-50 µm, 71.2 letters; >50-100 µm, 71.3 letters; >100 µm, 69.2 letters) versus no SRF (63.6 letters), but the change in BCVA from baseline to M12 or M24 was the same for eyes with or without treatment-resistant subretinal fluid (TR-SRF) at M3 or M6. CONCLUSION: TR-SRF was not detrimental to vision outcomes over 2 years, regardless of thickness. MA rates were significantly higher without TR-SRF.
引用
- Zarbin MA, Hill L, Maunz A, et al. Anti-VEGF-resistant subretinal fluid is associated with better vision and reduced risk of macular atrophy. Br J Ophthalmol. 2021. PMID: 34039560. doi:10.1136/bjophthalmol-2020-318688
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。